Get the latest news, insights, and market updates on AVIR (Atea Pharmaceuticals, Inc.). Explore the news page 1 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.
Atea Pharmaceuticals Q4 Earnings Call Highlights
Atea Pharmaceuticals (NASDAQ:AVIR) outlined progress in its hepatitis C (HCV) late-stage development program and provided an update on its newly expanded hepatitis E virus (HEV) pipeline during its fourth quarter and full-year 2025 financial results conference call. Management also discussed commerc Mar 5, 2026 - $AVIR
Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
Advanced Global Phase 3 Program for Treatment of Hepatitis C Virus (HCV) in 2025 with Topline Results from North American C-BEYOND Trial Expected Mid-2026 and Topline Results from C-FORWARD Trial Outside North America Anticipated Year-End 2026 Presented Results Reinforcing Bemnifosbuvir/Ruzasvir as a Potential Best-in-Class Regimen for the Treatment of HCV at the 2025 EASL Congress and The Liver Meeting® 2025, the Annual Meeting of AASLD Physician KOLs Underscored the Need for a New Optimized HC Mar 5, 2026 - $AVIR
Atea Pharmaceuticals to Host Fourth Quarter and Full Year 2025 Financial Results and Business Update Conference Call on March 5, 2026
BOSTON, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a late-stage clinical biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced that it will host a live conference call and audio webcast on Thursday, March 5, 2026, at 4:30 p.m. ET to report financial results for the fourth quarter and full year ended December 31, 2025, and to provide a business update. To acc Feb 26, 2026 - $AVIR
Atea Pharmaceuticals Presents Preclinical Results Supporting First-in-Class Potential of AT-587 for Treatment of Hepatitis E Virus at CROI 2026
Results Demonstrate AT-587 To Be Highly Potent In Vitro Against Hepatitis E Virus Initiation of Phase 1 Clinical Program Anticipated Mid-2026 BOSTON, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a late-stage clinical biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced in vitro results showing that two proprietary oral nucleotide analogs, AT-587 and AT-2490, Feb 24, 2026 - $AVIR
Spotlight On Atea Pharmaceuticals And 2 Other Noteworthy Penny Stocks
Major stock indexes in the United States have experienced a mixed performance recently, reflecting ongoing market volatility and economic uncertainties. Amid these fluctuations, penny stocks remain an intriguing area for investors seeking opportunities in smaller or newer companies. Despite their vintage name, penny stocks can still offer significant value and growth potential when backed by strong financials. In this article, we'll explore three noteworthy examples of such stocks that may... Jan 23, 2026 - $AVIR
We use cookies and similar technologies to collect and process data such as browsing activity or unique identifiers.
Selecting "Allow All" to help us understand site usage and improve the platform.
Choosing "Essential Cookies Only" enables only the cookies necessary for core site functions, such as staying logged in.
For more information, please see our Privacy Policy.
Continue with Google
Continue with Facebook
Continue with Microsoft
Continue with Apple